Results 61 to 70 of about 411,149 (312)

Nanomaterials for cancer immunotherapy [PDF]

Biomaterials, 2017
Cancer immunotherapy is quickly growing to be the fourth most important cancer therapy, after surgery, radiation therapy, and chemotherapy. Immunotherapy is the most promising cancer management strategy because it orchestrates the body's own immune system to target and eradicate cancer cells, which may result in durable antitumor responses and reduce ...
Song, Wantong, Musetti, Sara N., Huang, Leaf   +2 more
openaire   +2 more sources

An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.

, 2022
UNLABELLED: Mutations in oncogenes such as KRAS and EGFR cause a high proportion of lung cancers. Drugs targeting these proteins cause tumor regression but ultimately fail to elicit cures.
Romero-Clavijo, P, East, P, Moore, C, Durfee, C, Coelho, MA, Suárez-Bonnet, A, Murillo, M, Priestnall, SL, Larson, LK, Ross, SJ, Swanton, C, Law, EK, Ng, KW, Hancock, DC, Vogel, RI, Rana, S, Mugarza, E, Harris, R, de Carné Trécesson, S, Molina-Arcas, M, Boumelha, J, Brown, WL, Downward, J, Argyris, PP, Caswell, DR, Kassiotis, G   +25 more
core   +1 more source

Interrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer

Molecular Oncology, EarlyView.
COLOSSUS project RAS‐mutated MSS colon cancer study explored transcriptomics and immune cell density by immunohistochemistry (IHC), Immunoscore (IS), ISIC/TuLIS scores, mutation counts, and detected different prevalences but similar microenvironment composition across immune markers with clinical relevance for future immunotherapy combination ...
Rodrigo Dienstmann, Eduardo García‐Galea, Alice O'Farrell, Zak Kinsella, Maxime Meylan, Florent Petitprez, Ingrid Arijs, Tom Venken, Hari Ps, Adrian Lärkeryd, Ian Miller, Janick Selves, Nadja Meindl‐Beinker, Fiorella Ruiz‐Pace, Elena Élez, Raquel Comas‐Navarro, Frank Lincoln, Dirk Fey, Gift Nyamundanda, Aoife Nolan, Joern Lewin, Raquel Perez‐Lopez, Jonathan Briody, Kathleen Bennett, Walter Kolch, David Matallanas, Alexander Kel, Enrique Arenas, Joaquín Arribas, Bart Ghesquière, Josep Tabernero, Julie Meilleroux, Deborah McNamara, Ray McDermott, Marvin Lim, Mary O'Reilly, Brian Bird, Lisa Stack, Lucia Moloney, Patrick Morris, Keith Egan, Maciej Milewski, Lars Scheuer, Joachim Behringer, Georg Bolz, Ramon Salazar, Cristina Santos, Andrea Ruiz, Orla Casey, Verena Murphy, Matthias Ebert, Livio Trusolino, Diether Lambrechts, Anguraj Sadanandam, Catherine Sautès‐Fridman, Jochen Prehn, Paolo Nuciforo, Jacques Fieschi, Florence Monville, Darran O'Connor, Wolf Fridman, Annette Byrne   +61 more
wiley   +1 more source

Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer

Forum of Clinical Oncology, 2016
Strong evidence points to the role of cancer immunoediting and tumor immune infiltrates in regulating cancer progression. By understanding the immune tumor microenvironment, we can now target key pathways that suppress endogenous antitumor responses ...
Pistamaltzian Nikolaos F., Perez Sonia A., Baxevanis Constantin N.   +2 more
doaj   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study)

Technology in Cancer Research & Treatment
Objective: The prognosis of malignant tumors with peritoneal metastases and cancerous ascites has generally been poor, with limited treatment options.
Yingying Xu MS, Yuehong Kong MS, Yifu Ma MS, Meiling Xu MS, Jiabao Yang MS, Junjun Zhang PhD, Rongzheng Chen MS, Guangqiang Chen MS, Zhihui Hong MS, Xiangrong Zhao MS, Chenyang Zhang MS, Pengfei Xing MS, Liyuan Zhang MD, Peifeng Zhao MS   +13 more
doaj   +1 more source

Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies

Journal for ImmunoTherapy of Cancer, 2018
Mutation-derived neoantigens represent an important class of tumour-specific, tumour rejection antigens, and are attractive targets for TCR gene therapy of cancer.
Vanessa M. Tubb, Deborah S. Schrikkema, Nathan P. Croft, Anthony W. Purcell, Carsten Linnemann, Manon R. Freriks, Frederick Chen, Heather M. Long, Steven P. Lee, Gavin M. Bendle   +9 more
doaj   +1 more source

Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.

, 2020
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking.
Curvietto, M, Di Franco, R, Di Lauro, V, Pietroluongo, E, Simeone, E, Giannarelli, D, Piantedosi, F, Messina, M, Zivi, A, Conca, R, Vari, S, Picozzi, F, Pagliuca, M, Daniele, B, De Santo, I, Federico, P, Messina, C, Zampiva, I, Russo, A, Tortora, M, Marretta, AL, von Arx, C, Rescigno, P, Bosso, D, Morabito, A, Gridelli, C, Minisini, AM, Giordano, P, Grimaldi, AM, Montesarchio, V, Giuliano, M, SCITO (Società Campana di ImmunoTerapia Oncologica),, Nappi, L, Cavallero, D, Sbrana, A, Vitiello, F, Paciolla, I, Vanella, V, Attademo, L, Vivaldi, C, Milano, M, Parola, S, De Placido, S, Massa, V, Cartenì, G, Napolitano, F, De Falco, S, Morgillo, F, Palmieri, G, De Felice, M, De Stefano, A, Tomei, F, Ascierto, PA, Della Corte, CM, Piccin, L, Aieta, M, Ciardiello, F, De Placido, P, Mennitto, A, Rosanova, M, Cavo, A, Lia, M, Borzillo, V, Festino, L, Santabarbara, G, Prati, V, De Laurentiis, M, Spada, M, Bloise, F, Vincenzo, T, Trojanello, C, Riccio, V, Merler, S, Tarantino, P, Trapani, D, Assalone, P, Caputo, F, Conteduca, V, Buono, G, Fabbrocini, A, Silvestri, A, Zacchi, F, Mucci, B, Petrillo, A, Calderoni, G, Pepe, S, Pignata, S, Taveggia, P, Ventriglia, J, Avallone, A, Ottaviano, M, Merz, V, Vitale, MG, Rossi, A, Salati, M   +94 more
core   +1 more source

How Did Conventional Nanoparticle-Mediated Photothermal Therapy Become "Hot" in Combination with Cancer Immunotherapy?

, 2022
Simple Summary Photothermal therapy (PTT) has become effective through the development of nanoparticle-based photoabsorbers with various functions, such as targeting properties, high light-to-heat conversion, and photostability. Conventional nanoparticle-
Yun, Wan Su, Ji-Ho Park, Kwangmeyung Kim, Park, Ji-Ho, Lim, Dong-Kwon, Dong-Kwon Lim, Kim, Kwangmeyung, Sun, In-Cheol, Cheol-Hee Ahn, Ahn, Cheol-Hee, In-Cheol Sun, Wan Su Yun   +11 more
core   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source